CN107281231A - The preparation and application of seed of Oriental arborvitae active component - Google Patents
The preparation and application of seed of Oriental arborvitae active component Download PDFInfo
- Publication number
- CN107281231A CN107281231A CN201610190057.1A CN201610190057A CN107281231A CN 107281231 A CN107281231 A CN 107281231A CN 201610190057 A CN201610190057 A CN 201610190057A CN 107281231 A CN107281231 A CN 107281231A
- Authority
- CN
- China
- Prior art keywords
- seed
- active component
- oriental arborvitae
- dementia
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000002924 Platycladus orientalis Species 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 27
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 11
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 8
- 206010012289 Dementia Diseases 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 241000218645 Cedrus Species 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000015654 memory Effects 0.000 abstract description 5
- 230000001713 cholinergic effect Effects 0.000 abstract description 4
- 210000005036 nerve Anatomy 0.000 abstract description 4
- 208000037259 Amyloid Plaque Diseases 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000001320 hippocampus Anatomy 0.000 description 13
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 12
- 238000011830 transgenic mouse model Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 101150060184 ACHE gene Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012347 Morris Water Maze Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- -1 Garland His quick Chemical compound 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the preparation of seed of Oriental arborvitae active component and application, it is characterized in that seed of Oriental arborvitae active component is preparing the application in preventing and treating senile dementia medicine, health products, wherein seed of Oriental arborvitae active component content is no less than 60%.Proved through experimental study, seed of Oriental arborvitae active component can improve animal pattern memory disorders, improve its ability of learning and memory；The generation of senile plaque expelling is reduced, is effectively improved, adjusts cholinergic nerve of centrum system, adjust a variety of effects such as Radical Metabolism.The active component is to senile dementia, including Alzheimer's disease, vascular dementia, Mixed dementia etc. have definite curative effect.
Description
Technical field
The present invention relates to the preparation of seed of Oriental arborvitae active component and application, more particularly to seed of Oriental arborvitae active component is preventing or controlled
The application in senile dementia medicine, health products is treated, belongs to field of medicaments category.
Background technology
Senile dementia mainly includes Alzheimer disease (AD) and vascular dementia (VD), and Alzheimer disease accounts for 60
~70%, vascular dementia accounts for 20~30%.Alzheimer disease（Alzheimer ’s disease, AD）Be it is a kind of with
The degenerative disease of central nervous system based on progressive dementia.Its Clinical symptoms is to remember and other cognition dysfunctions,
Early clinic symptom includes motion, felt or coordination function defect.The main pathological change of AD patient is extracellular amyloid
Albumen precipitation formation senile plaque expelling, the missing of NFT and extensive synapse, inflammation, oxidation are even bad
Extremely.
With the development and the aging of population of society, the morbidity of Alzheimer disease increases with the growth at age.Root
According to the World Health Organization（WHO）With international Alzheimer disease association（ADI）Statistics, the whole world is with dull-witted patient's estimation at present
47,000,000 or so, wherein patients with Alzheimer disease constitutes about 60%-70%.This numeral increases by 1 times in estimated every 20 years, i.e., every
Some corner of 4 seconds earth occurs as soon as a new dull-witted case.Dull-witted illness rate and huge consuming are to society and scientific research
With huge challenge, but up to the present, also Alzheimer disease, research work can be fundamentally treated without a kind of medicine
Persons have suffered repeated defeats during the last ten years, fight repeatedly after suffering repeated defeats.
AD pathogenesis is complicated, at present both at home and abroad still without can treat AD medicine at all, therefore early treatment is to closing again
Will.The medicine listed at present is broadly divided into two kinds, and one kind is anticholinesterase, such as Doneppezil Hydrochloride, Garland
His quick, rivastigmine, huperzine are first-class；Another is excitatory amino acid receptor antagonists, such as memantine.Separately
There are anti-inflammatory, anti-oxidant, anti-cholesterol, anti-beta amyloid class medicine to be used for AD auxiliary treatment.Said medicine can improve in short term
The symptom of AD patient, but advancing of disease can not be alleviated, and resistance is easily formed, adverse reaction is obvious；And traditional Chinese medicine is light in preventing and treating
Degree cognitive disorder and senile dementia have preferable clinical effectiveness, have multipath, the characteristics of too many levels is integrally-regulated, and use
The toxic side effect of natural drug is small.Therefore, the extraction of traditional Chinese medicine monomer or its active principle has very heavy applied to AD preventing and treating
The meaning wanted.
The seed of Oriental arborvitae（arboruitae seed）, also known as cypress is real, is the dry mature kernal of gymnosperm Cupressaceae arbor-vitae.It
Flat property and sweet taste, enters the heart, liver, kidney, large intestine channel, with antitoxic heart-soothing and sedative, and arrest sweating promotes the production of body fluid, the effect of relaxing bowel, and is conventional Chinese medicine
Material, applicating history is long, first recorded in《Sheng Nong's herbal classic》, it is classified as top grade.《Compendium of Materia Medica》Record：Seed of Oriental arborvitae tool " nourishing heart gas, profit
Kidney is dry, and peace soul determines soul, and intelligence development is allayed excitement；Zetou is sent out, and controls mange." effect, for palpitation of palpitating with fear, insomnia forgetfulness, night sweat, intestinal dryness is just
It is secret to wait disease.Modern pharmacological research shows that the seed of Oriental arborvitae has preferable curative effect in all many-sides, is widely used in and faces in prescription form more
Bed.Current pharmacological research find seed of Oriental arborvitae water and its alcohol extract to the memory caused by scopolamine, consolidate obstacle, electricity
Study, which reproduces obstacle etc., caused by memory consolidation obstacle, ethanol caused by fainting from fear improvement result, and the seed of Oriental arborvitae can make sound sleep
Time is obviously prolonged, and growth of the seed of Oriental arborvitae ligroin extraction to chick embryonic dorsal root ganglion projection has slight growth promoting function.This
Inventor is further study show that a kind of seed of Oriental arborvitae active component can significantly improve AD Cognition Function in Rats obstacles, and it is to anti-punish-old
Dementia is significant.
The content of the invention
The present invention uses the seed of Oriental arborvitae, and extraction processing is carried out to it, using seed of Oriental arborvitae active component as main medicinal component, plus
Enter proper auxiliary materials, be prepared into the preventions of various senile dementias such as suitable preparation Alzheimer's disease, vascular dementia and
Treatment.
Seed of Oriental arborvitae active component of the present invention is prepared from according to following preparation technology, and its processing step is
（1）Take seed of Oriental arborvitae medicinal material to clean, dry, pulverize into coarse powder；
（2）The ethanol of 10~15 times of amounts of seed of Oriental arborvitae coarse powder, 50 DEG C~65 DEG C refluxing extractions 2~4 times, 2~6h every time, filtering,
Merge filtrate twice, filtrate is concentrated to give medicinal extract；
（3）By gained medicinal extract add 4 times amount water dissolving after adsorbed with macroporous resin column, be then washed with deionized water to efflux without
Color is eluted with ethanol solution again；
（4）Merge the eluent after macroporous resin purification, concentrated with rotary evaporator, evaporated in vacuo obtains cedar seed at 55~65 DEG C
Benevolence active component.
Step（2）Described in the seed of Oriental arborvitae active component preparation method, it is characterised in that with 10 times amount 75~95% ethanol
Refluxing extraction 4 times, extract 4h every time at 60 DEG C.
Step（3）Described in the seed of Oriental arborvitae active component preparation method, it is characterised in that macroreticular resin model can select
D101, D4020, D3520, D4006HPD-500, HP-20, H103, NKA-9, NKA-2, X-5, XAD-4 etc..
Step（3）Described in the seed of Oriental arborvitae active component preparation method, it is characterised in that the preferred D101 of macroreticular resin model.
Step（3）Described in the seed of Oriental arborvitae active component preparation method, it is characterised in that ethanol is washed after macroporous resin adsorption
De- concentration is 50%~95%.
Step（3）Described in the seed of Oriental arborvitae active component preparation method, it is characterised in that ethanol is washed after macroporous resin adsorption
De- concentration is preferably 95%.
Step（4）Described in preferably 60 DEG C of vacuum drying temperature.
It mainly contains seed of Oriental arborvitae saponin(e to the active component of the seed of Oriental arborvitae of the present invention, and its active component content is more than
60%。
Purposes of the active component of the seed of Oriental arborvitae of the present invention in the medicine for preventing and treating senile dementia, health products are prepared.
Senile dementia of the present invention is that Alzheimer disease, vascular dementia, Alzheimer disease and vascular are silly
The Mixed dementia stayed and deposited is one or more of.
Senile dementia of the present invention is mainly Alzheimer disease.
The medicine of preventing and treating senile dementia of the present invention or the preparation method of health products, it is characterised in that：Its formulation is ball
Agent, granule, tablet, syrup, mixture, capsule, tincture, medicinal tea, injection.
The active component for the seed of Oriental arborvitae that the present invention is provided can be also used for preparing food supplement and/or health care food
Product, can be prepared into the various formulations of health food, such as tablet, capsule, oral liquid, health drink, health protection tea；Also may be used
Using as food additives, applied to food（Such as bread, noodles）, health protection tea, health drink etc..
Embodiment
The invention is further described below by specific embodiment.
Embodiment 1：Seed of Oriental arborvitae active component preparation technology
（1）Take 1000g seed of Oriental arborvitaes medicinal material to clean, 60 mesh sieves are crossed after dry, pulverize, coarse powder is obtained；
（2）Seed of Oriental arborvitae coarse powder 75% ethanol of 10 times of amounts, 60 DEG C of refluxing extractions 4 times, each 4h, filtering merges filtrate twice,
Filtrate is concentrated to give medicinal extract；
（3）Adsorbed, be then washed with deionized water to outflow with D101 macroporous resin columns after gained medicinal extract is added into 4 times of amount water dissolvings
Liquid is colourless to be eluted with 95% ethanol solution again；
（4）Merge the eluent after macroporous resin purification, concentrated with rotary evaporator, evaporated in vacuo, which obtains the seed of Oriental arborvitae, at 60 DEG C has
Imitate position.
Embodiment 2：Have shown that seed of Oriental arborvitae active component there is treatment to make APP/PS1 double transgenics dementia mice in body research
With
1 material
1.1 experimental animal
5 monthly age APP/PS1 bi-transgenic mices 48, male, body weight 25 ± 2g, SPF grade, identical genetic background C57BL/6J is small
Mouse 8 is normal control.
1.2 Experimental agents and reagent
Positive control medicine selects Doneppezil Hydrochloride (trade name：Aricept), tablet is ground into powder by 5mg/ pieces using preceding
End, gavage decoction 0.65mg/kgd is configured to distilled water- 1；Huperzine A capsule is configured to gavage decoction with distilled water, matches somebody with somebody
Concentration processed is 0.026mg/kgd- 1.Acetylcholinesterase (AChE) kit, cholinacetyltranslase (ChAT) reagent
Box, SOD active agents box, MDA contents kit, GSH content kits.Seed of Oriental arborvitae active component prepares gained by embodiment 1.
1.3 key instrument
DMS-2 type Morris water maze instrument automatic data collections and processing system, BH-2 type biomicroscopes, DpxView Pro
Type computer color vision processing system, paraffin section device, Full automatic closed tissue processor, embedding machine, pathological tissue
Instrument is dried in drift, and Image-Pro Plus image analysis systems freeze at a high speed refrigerated centrifuge.
2 methods
2.1 packets and administration
By the body weight principle of correspondence, APP/PS1 bi-transgenic mices are divided into model group, seed of Oriental arborvitae active component low dosage at random
Group (30mg/kg/d), seed of Oriental arborvitae active component middle dose group (60mg/kg/d), seed of Oriental arborvitae active component high dose group (120mg/
Kg/d), Doneppezil Hydrochloride group (0.65mg/kg/d) and huperzine group（0.026mg/kg·d）, every group 8；Identical heredity
The same monthly age C57BL/6J mouse 8 of background are only used as Normal group.Normal group and model group give isometric distilled water gavage,
One time a day.Each group mouse stomach 8 weeks, to progress Morris water maze tests during 7 monthly age.
2.2 brain tissue samples are handled
Mouse is in after last Behavior test, and fasting 12h carries out brain tissue materials.Pathology and SABC are carried out to brain tissue
The experiments such as dyeing, tissue content measure.
2.4 statistical procedures
The data obtained represents that carrying out data between statistical analysis, group using statistic software SPSS 18.0 compares with mean ± standard deviation
With one-way analysis of variance, examined using LSD, Dunnett ' sC (during heterogeneity of variance), be that difference has conspicuousness meaning with P ＜ 0.05
Justice.Orientation navigation experiment is using the variance analysis of Repeated Measurements, space exploration examination during behaviouristics Morris water mazes are determined
Test and use one-way analysis of variance.
3 experimental results
Seed of Oriental arborvitae active component influences on APP/PS1 bi-transgenic mices ability of learning and memory in 3.1 Morris water maze laboratories
As a result show, compared with blank control group, the escape latency of model group significantly extends（P ＜ 0.01）, the platform residence time show
Write and reduce（P ＜ 0.05）, spanning platform number of times substantially reduces（P ＜ 0.01）；Compared with model group, agent in seed of Oriental arborvitae active component
Amount group（P ＜ 0.05）, high dose group（P ＜ 0.01）With positive drug Doneppezil Hydrochloride group（P ＜ 0.05）Escape latency is notable
Reduce, the seed of Oriental arborvitae active component middle dose group target quadrant residence time（P ＜ 0.05）Dramatically increased with spanning platform number of times（P
＜ 0.01）, illustrate that seed of Oriental arborvitae active component can improve learning and memory in rats ability；Compared with positive drug, the effective portion of the seed of Oriental arborvitae
Position high dose group incubation period is shorter than positive drug group, seed of Oriental arborvitae active component middle dose group target quadrant residence time and spanning platform
Number of times is more than positive drug group, illustrates that raising effect of the seed of Oriental arborvitae active component to learning and memory in rats ability is better than positive drug（See
Table 1）.
Influence of the seed of Oriental arborvitae active component of table 1 to APP/PS1 bi-transgenic mice Spatial memory abilities
| Group | Quantity | Escape latency (s) | Target quadrant traversing times | The platform residence time (s) | The target quadrant residence time (s) | Spanning platform number of times |
| Blank control group | 8 | 18.3±1.9 | 3.4±0.3 | 1.6±0.2 | 10.3±0.8 | 3.4±0.5 |
| Model group | 8 | 36.4±3.6## | 2.7±0.3 | 0.7±0.1# | 7.4±0.6 | 1.6±0.1## |
| Seed of Oriental arborvitae active component low dose group | 8 | 31.1±3.0 | 3.5±0.3 | 1.3±0.1 | 9.6±0.9 | 1.9±0.2 |
| Seed of Oriental arborvitae active component middle dose group | 8 | 24.7±2.6* | 2.1±0.2 | 0.8±0.1 | 11.5±1.2* | 2.7±0.3** |
| Seed of Oriental arborvitae active component high dose group | 8 | 23.1±3.1** | 3.7±0.4 | 1.0±0.1 | 10.4±1.0 | 2.2±0.4* |
| Doneppezil Hydrochloride group | 8 | 26.7±2.5* | 3.3±0.3 | 1.1±0.1 | 9.7±0.8 | 1.9±0.3 |
| Huperzine group | 8 | 30.2±3.4 | 4.2±0.4* | 1.4±0.1* | 11.0±1.1* | 2.1±0.34 |
Compared with blank control group,#P ＜ 0.05,##P ＜ 0.01；Compared * P ＜ 0.05, * * P ＜ 0.01 with model group
3.2 seed of Oriental arborvitae active components are to cholinacetyltranslase in APP/PS1 bi-transgenic mice hippocampus（AchE）With acetyl courage
Alkali esterase（ChAT）The influence result of activity is shown, is compared with blank control group, and the Ach contents of model group are significantly reduced, AchE
Activity is dramatically increased, ChAT activity is substantially reduced；Compared with model group, seed of Oriental arborvitae active component high dose group（P ＜ 0.05）With
The Ach contents of positive drug group are dramatically increased, and AchE activity is substantially reduced, ChAT activity is dramatically increased, and illustrate the effective portion of the seed of Oriental arborvitae
Position can increase hippocampus of mice acetyl choline content by adjusting cholinergic nerve system（It is shown in Table 2）.
Influence of the seed of Oriental arborvitae active component of table 2 to Ach, AchE and ChAT content in APP/PS1 bi-transgenic mice hippocampus
| Group | Dosage mg/kg | Ach（ug/ml） | AchE( U/g) | ChAT( U/g) |
| Blank control group | 134.51±11.06 | 220.31±18.29 | 42.17±4.08 | |
| Model group | 90.32±8.22# | 421.53±31.08### | 24.18±2.84# | |
| Seed of Oriental arborvitae active component low dose group | 30.0 | 112.07±10.39 | 333.57±31.22 | 26.98±2.22 |
| Seed of Oriental arborvitae active component middle dose group | 60.0 | 101.58±9.91 | 359.88±34.68 | 30.83±2.95 |
| Seed of Oriental arborvitae active component high dose group | 120.0 | 128.57±11.12* | 298.24±28.17* | 32.07±3.14* |
| Doneppezil Hydrochloride group | 0.65 | 141.01±12.78* | 287.79±25.15** | 36.76±4.18** |
| Huperzine group | 0.026 | 131.58±12.64* | 294.13±28.75* | 35.88±3.63** |
Compared with blank control group,#P ＜ 0.05,###P ＜ 0.001；Compared * P ＜ 0.05, * * P ＜ 0.01 with model group
3.3 seed of Oriental arborvitae active components are to APP/PS1 bi-transgenic mice hippocampus person in middle and old age's spots（SP）Influence result show, with sky
White control group compares, and SP quantity is dramatically increased in model group hippocampus of mice（P ＜ 0.001）；Compared with model group, the seed of Oriental arborvitae is effective
Position high dose group（P ＜ 0.01）With positive drug Doneppezil Hydrochloride group（P ＜ 0.05）SP quantity is substantially reduced in hippocampus of mice,
Illustrate that seed of Oriental arborvitae active component can reduce APP/PS1 bi-transgenic mice hippocampus person in middle and old age spot deposition（It is shown in Table 3）.
The seed of Oriental arborvitae active component of table 3 is to APP/PS1 bi-transgenic mice hippocampus person in middle and old age's spots（SP）Influence
| Group | Dosage mg/kg | Size of animal | SP quantity（It is individual） |
| Blank control group | 8 | 4.1±0.8 | |
| Model group | 8 | 57.6±5.0### | |
| Seed of Oriental arborvitae active component low dose group | 30.0 | 8 | 34.7±3.8 |
| Seed of Oriental arborvitae active component middle dose group | 60.0 | 8 | 39.4±5.7 |
| Seed of Oriental arborvitae active component high dose group | 120.0 | 8 | 27.8±2.6** |
| Doneppezil Hydrochloride group | 0.65 | 8 | 30.1±2.7* |
| Huperzine group | 0.026 | 8 | 33.9±3.5 |
Compared with blank control group,###P ＜ 0.001；Compared * P ＜ 0.05, * * P ＜ 0.01 with model group
3.4 seed of Oriental arborvitae active components show to APP/PS1 bi-transgenic mice hippocampus SOD activity, MDA contents, the result of GSH contents
Show and compared with blank control group, the SOD activity of model group is substantially reduced, MDA contents are dramatically increased, GSH contents are substantially reduced；With
Model group compares, seed of Oriental arborvitae active component middle dose group（P ＜ 0.05）, high dose group（P ＜ 0.01）With positive drug group（P ＜
0.01）SOD activity is dramatically increased, seed of Oriental arborvitae active component high dose group and positive drug group（P ＜ 0.05）MDA contents significantly subtract
It is few；Illustrate that seed of Oriental arborvitae active component can improve the oxidation resistance of Rat hippocampus（It is shown in Table 4）
Influence of the seed of Oriental arborvitae active component of table 4 to SOD activity, MDA contents, GSH contents in bi-transgenic mice hippocampus
| Group | SOD(U/mgprot) | MDA(nmol/mgprot) | GSH(mg/gprot) |
| Blank control group | 48.85±4.12 | 2.85±0.33 | 6.38±0.61 |
| Model group | 25.56±2.88# | 6.47±0.68## | 4.25±0.35# |
| Seed of Oriental arborvitae active component low dose group | 31.87±3.09 | 3.77±0.36 | 3.94±0.66 |
| Seed of Oriental arborvitae active component middle dose group | 46.51±4.55* | 4.18±0.40 | 5.24±0.75 |
| Seed of Oriental arborvitae active component high dose group | 57.23±6.05** | 3.58±0.32* | 4.88±0.61 |
| Doneppezil Hydrochloride group | 56.14±5.25** | 3.71±0.24* | 5.28±0.52 |
| Huperzine group | 64.20±6.11** | 3.12±0.40* | 5.15±0.51 |
Compared with blank control group,#P ＜ 0.05,##P ＜ 0.01；Compared * P ＜ 0.05, * * P ＜ 0.01 with model group
4 conclusions
Seed of Oriental arborvitae active component can improve APP/PS1 double transgenic dementia mice cognition dysfunctions；Seed of Oriental arborvitae active component can
To adjust cholinergic nerve system increase hippocampus of mice acetyl choline content, senile plaque expelling is reduced（SP）Occur；The effective portion of the seed of Oriental arborvitae
Position can improve the oxidation resistance of Hippocampus of Mice, increase SOD activity, reduction MDA contents, increase GSH contents.
The medicine that the present invention treats senile dementia using seed of Oriental arborvitae active component as preparing, is tried using related pharmacology
Test and carry out seed of Oriental arborvitae active component and prevent and treat the pharmacodynamic evaluation of senile dementia, respectively from improve cholinergic nerve of centrum system,
In terms of suppressing amyloid beta (A β) formation and deposition, neuroprotection, illustrate seed of Oriental arborvitae active component multipath, Mutiple Targets and control
Treat the purposes of senile dementia.
Claims (8)
1. a kind of active component of the seed of Oriental arborvitae, it is obtained by following method：
（1）Take seed of Oriental arborvitae medicinal material to clean, dry, pulverize into coarse powder；
（2）The ethanol of 10~15 times of amounts of seed of Oriental arborvitae coarse powder, 50 DEG C~65 DEG C refluxing extractions 2~4 times, 2~6h every time, filtering,
Merge filtrate twice, filtrate is concentrated to give medicinal extract；
（3）By gained medicinal extract add 4 times amount water dissolving after adsorbed with macroporous resin column, be then washed with deionized water to efflux without
Color, then eluted with ethanol solution；
（4）Merge the eluent after macroporous resin purification, concentrated with rotary evaporator, evaporated in vacuo obtains cedar seed at 55~65 DEG C
Benevolence active component.
2. the active component preparation method of the seed of Oriental arborvitae according to claim 1, it is characterised in that with the 50%~95% of 10 times of amounts
Ethanol refluxing extraction 4 times at 60 DEG C, extract 4h every time.
3. the active component preparation method of the seed of Oriental arborvitae according to claim 1, it is characterised in that macroreticular resin model can select
D101, D4020, D3520, D4006HPD-500, HP-20, H103, NKA-9, NKA-2, X-5, XAD-4 etc..
4. the active component preparation method of the seed of Oriental arborvitae according to claim 1, it is characterised in that ethanol after macroporous resin adsorption
Wash-out concentration is 50%~95%.
5. a kind of active component of the seed of Oriental arborvitae containing described in Claims 1-4 is prevented and treated the medicine of senile dementia preparing, protected
Purposes in strong product.
6. according to claim 5, it is characterised in that：The senile dementia be Alzheimer disease, vascular dementia, Ah
Alzheimer's disease and vascular dementia and the Mixed dementia one or more deposited.
7. according to claim 6, it is characterised in that：The senile dementia is mainly Alzheimer disease.
8. the medicine of senile dementia or the preparation method of health products are prevented and treated according to claim 1 to 7, it is characterised in that：Its
Formulation is pill, granule, tablet, syrup, mixture, capsule, tincture, medicinal tea, injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610190057.1A CN107281231A (en) | 2016-03-30 | 2016-03-30 | The preparation and application of seed of Oriental arborvitae active component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610190057.1A CN107281231A (en) | 2016-03-30 | 2016-03-30 | The preparation and application of seed of Oriental arborvitae active component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281231A true CN107281231A (en) | 2017-10-24 |
Family
ID=60086635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610190057.1A Pending CN107281231A (en) | 2016-03-30 | 2016-03-30 | The preparation and application of seed of Oriental arborvitae active component |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281231A (en) |
-
2016
- 2016-03-30 CN CN201610190057.1A patent/CN107281231A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 兰黛公主: "柏子仁的功效与作用", 《HTTP://WWW.360DOC.COM/CONTENT/12/0924/00/2831026_237844454.SHTML》 * |
| 卢君等: "柏子仁皂苷提取工艺研究", 《中医临床研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7824714B2 (en) | Chinese herb extract for treating dementia and preparation method thereof | |
| JP2008502711A (en) | Carrot composition for preventing or improving deterioration of concentration and memory | |
| CN105920476B (en) | Traditional Chinese medicine composition for preventing and treating Alzheimer disease and preparation method thereof | |
| CN102014931B (en) | Use and preparation of paeoniflorin and the composition thereof | |
| RU2564093C2 (en) | COMPOSITION, CONTAINING Andrographis paniculata AND Ginkgo biloba EXTRACTS IN COMBINATION WITH PHOSPHOLIPIDS | |
| CN106581335A (en) | Medicine composition for treating Alzheimer's disease and preparing method and application thereof | |
| BR112017005416B1 (en) | pharmacological composition for use in medicine to treat or prevent degenerative neurological diseases containing as active ingredient extract of a mixture of mountain peony root bark, angelica dahurica root and bupleurum root or fragments thereof | |
| CN102670642A (en) | Traditional Chinese compound medicament for treating fatty liver disease | |
| WO2012175018A1 (en) | Traditional chinese medicine composition for promoting nerve regeneration and preparation method and use thereof | |
| CN109925402A (en) | A kind of Chinese medicine composition and the preparation method and application thereof | |
| CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
| CN109833320B (en) | Application of ginsenoside in preparation of product for activating TMEM16A ion channel, activator, kit and medicine | |
| KR101796923B1 (en) | Composition for treating neurodegenerative disorders containing ginseng berry extracts | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN106692145B (en) | Medicine for treating vascular dementia | |
| CN102631397B (en) | Traditional Chinese medicine composition for improving cerebral blood circulation and preparation method thereof | |
| CN107281231A (en) | The preparation and application of seed of Oriental arborvitae active component | |
| KR20190044862A (en) | Composition comprising ethanol extract of Aster scaber for preventon or treatment of neuropathic pain | |
| CN111053819A (en) | Traditional Chinese medicine composition extract and application thereof in preparation of protein expression regulator | |
| CN108295168B (en) | Traditional Chinese medicine composition for treating post-stroke depression | |
| CN112220870A (en) | Pharmaceutical composition for treating Alzheimer disease | |
| CN107281207A (en) | Astragaloside I is preparing the purposes in preventing and treating the medicine or health products of senile dementia | |
| EP2845589B1 (en) | Composition for the prevention and treatment of migraine or neuropathic pain | |
| CN108371712A (en) | Caffeine combines the purposes prepared in AD drugs with PPAR gamma agonists | |
| TWI843562B (en) | Use of extract of cynara scolymus for manufacturing medicationfor treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171024 |
|
| WD01 | Invention patent application deemed withdrawn after publication |